FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
2024-11-13 5:55:10 PM | Chg. -0.340 | Volume | Bid6:07:16 PM | Ask6:07:16 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
32.840EUR | -1.02% | 451 Turnover: 14,765.740 |
32.660Bid Size: 2,100 | 33.040Ask Size: 2,100 | 18.41 bill.EUR | - | - |
GlobeNewswire
04-23
Transferring Biomedical Research to Patients Faster: ForTra gGmbH Announces Positive Funding Track R...
GlobeNewswire
02-23
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatm...
GlobeNewswire
2023-09-04
CIO Leadership: Generative AI and Visionary Leadership in the Enterprise Will Power the Discussion a...
GlobeNewswire
2023-08-31
CytoSorbents Granted Expanded ANVISA Registration to Treat Shock with CytoSorb in Brazil
GlobeNewswire
2023-08-24
CIO Leadership: The Steps Needed to Build a High-Performance Culture Will Power the Discussion at th...
GlobeNewswire
2022-02-25
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodia...
GlobeNewswire
2022-01-05
Oculis appoints Mr. Webb Ding as Global Chief Operating Officer and General Manager (China)
GlobeNewswire
2021-12-31
CIO Leadership: HMG Strategy, the World’s #1 Executive Leadership Network, Looks Ahead to its 15th Y...
GlobeNewswire
2021-12-09
Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surge...
GlobeNewswire
2021-11-22
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
GlobeNewswire
2021-11-22
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology